<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/6083E7FB-0220-4F5F-97B0-7F6113B49A0C"><gtr:id>6083E7FB-0220-4F5F-97B0-7F6113B49A0C</gtr:id><gtr:name>MRC Unit, The Gambia</gtr:name><gtr:address><gtr:line1>MRC Laboratories, The Gambia</gtr:line1><gtr:line2>Atlantic Road PO Box 273</gtr:line2><gtr:line4>Fajara</gtr:line4><gtr:region>Outside UK</gtr:region><gtr:country>Gambia</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6083E7FB-0220-4F5F-97B0-7F6113B49A0C"><gtr:id>6083E7FB-0220-4F5F-97B0-7F6113B49A0C</gtr:id><gtr:name>MRC Unit, The Gambia</gtr:name><gtr:address><gtr:line1>MRC Laboratories, The Gambia</gtr:line1><gtr:line2>Atlantic Road PO Box 273</gtr:line2><gtr:line4>Fajara</gtr:line4><gtr:region>Outside UK</gtr:region><gtr:country>Gambia</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/92243737-145F-406E-BEC4-4D90D321EDB6"><gtr:id>92243737-145F-406E-BEC4-4D90D321EDB6</gtr:id><gtr:firstName>Tom</gtr:firstName><gtr:surname>Peto</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_U190088489"><gtr:id>E6F028EF-3839-4BEE-BA51-492207FB9DDC</gtr:id><gtr:title>Vaccine effectiveness of routine infant hepatitis B vaccination/hepatitis B vaccine impact under immunisation programme</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_U190088489</gtr:grantReference><gtr:abstractText>We will check how well the hepatitis B vaccine is working by taking small blood samples from 7,700 people aged from 1 to 21 across the country. By comparing vaccinated people against unvaccinated we will see if the protection against infections with hepatitis B that was seen in earlier studies continues into adulthood. We need to do this as liver disease (especially liver cancer) caused by Hepatitis B is a major killer in The Gambia and as the vaccine was only introduced 21 years ago we do not yet know if the vaccinations given in childhood are going to prevent infections and disease in adults.</gtr:abstractText><gtr:technicalSummary>We propose to study the effectiveness of Hepatitis B (HBV) vaccination in infancy against chronic active hepatitis in early adulthood. This will provide new evidence to determine if there is continued protection against HBV carriage and disease after such a long period of time and whether it continues despite the onset of sexual activity. Additionally we will screen those born since the introduction of HBV vaccination into the Expanded Programme of Immunisation (EPI) to further measure the impact of routine vaccination, specifically: what level of carriage is present at different ages; how these appear to be acquired; if rates follow a trend over time; and if there has been a shift in the viral genotype. Approximately 3,200 17-21 year olds from the Gambia Hepatitis Intervention Study (GHIS) will have blood samples taken and 4,500 under 17s who were born since the end of the GHIS will be screened for HBV. This information will inform decisions on the value of a booster dose of vaccine in teenagers, whether there is perinatal transmission that can be averted by giving a first dose of the vaccine on the day of birth, and will describe the performance of the EPI in real life conditions. The existing GHIS, and the following early adoption of the HBV vaccine nationwide, makes this a unique population in which to answer these questions and further define the effectiveness of the HBV vaccine. The large number of blood samples collected will also allow for the genetic testing of host and viruses.</gtr:technicalSummary><gtr:fund><gtr:end>2008-06-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2007-04-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>985373</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Open day at the Medical Research Council Laboratories, The Gambia</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>3A77029C-23D9-496B-A829-F2C10D693E25</gtr:id><gtr:impact>We held a stall to explain hepatitis B to secondary school children.

We had good response from the children who attended.</gtr:impact><gtr:outcomeId>MmSkFektnmb</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Radio presentation in the Gambia</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>11E4F393-1C5A-4AFC-B3F2-EF777FF4C48F</gtr:id><gtr:impact>We presented a call-in show on Radio Basse to educate people about hepatitis B and inform communities of a study that we were conducting

We had people phone in with questions and we reached a wide audience</gtr:impact><gtr:outcomeId>J3Kyw4Tizzh</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Joint International Tropical Medicine Meeting</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>C7FDEAED-2F89-435F-A3BB-05EC3CFD5B66</gtr:id><gtr:impact>Presenting work from hepatitis B surveys in The Gambia at a medical conference

none</gtr:impact><gtr:outcomeId>SKeWqwbp2eJ</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation at the Clinical Trials Service Unit, University of Oxford</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>D9F62C88-7E3A-4841-A847-DCE47C993406</gtr:id><gtr:impact>presenting work from my PhD on hepatitis B in The Gambia

none</gtr:impact><gtr:outcomeId>b41cMgNjXuB</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation of data from Gambian HBV surveys to JCVI</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>C0A33ACC-F9E3-4BAE-95AB-84FF87D08D65</gtr:id><gtr:impact>Unpublished data from the 2007-08 GHIS survey was presented alongside all other HBV efficacy studies as part of a review.

Not yet known, data should confirm the long-term vaccine efficacy of infant HBV immunization in Africa.</gtr:impact><gtr:outcomeId>D1uedwk9mmv</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>visit to Ministry of Health in The Gambia</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:id>40AE84AF-9764-47F3-879E-F6961D3216EB</gtr:id><gtr:impact>Discussions with MoH Immunisation team in The Gambia

We are continuing to work in partnership with the health authorities in The Gambia as part of a long term collaboration &amp;quot;The Gambia Hepatitis Intervention Study&amp;quot;.</gtr:impact><gtr:outcomeId>BE52BD2EB31</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Community awareness meetings for hepatitis B surveys in The Gambia</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>5AC4AAEB-A269-413A-95C2-0A6DE06B3C25</gtr:id><gtr:impact>We held meetings to explain the study we were conducting

We had a good response.</gtr:impact><gtr:outcomeId>Jo5ZU5u5Ltq</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2007,2008</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>demonstration of long-term hepatitis B vaccine efficacy in Africa</gtr:description><gtr:geographicReach>Africa</gtr:geographicReach><gtr:id>C66A77FC-4599-4392-9068-86B7583B8786</gtr:id><gtr:outcomeId>MPWrYbfCnsc</gtr:outcomeId><gtr:type>Citation in other policy documents</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Under Dr Maimuna Mendy we have approximately 2,700 thousand sera samples and DNA samples from a cross-sectional study that are retained for future use by the Viral Diseases Programme.</gtr:description><gtr:id>135A3472-7903-476C-B7DE-A5409CCE2576</gtr:id><gtr:impact>results from these samples are still being analysed.</gtr:impact><gtr:outcomeId>70FB11AC537</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Hepatitis B vaccine efficacy survey 2007/8 sera samples and DNA samples stored in Fajara, The Gambia</gtr:title><gtr:type>Database/Collection of Data/Biological Samples</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>FDC3F63C-83C8-439E-8CA7-67CBE96A5B56</gtr:id><gtr:title>Observational study of vaccine efficacy 24 years after the start of hepatitis B vaccination in two Gambian villages: no need for a booster dose.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0cc8502cee018caa2dfd8752dd14a92d"><gtr:id>0cc8502cee018caa2dfd8752dd14a92d</gtr:id><gtr:otherNames>Mendy M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>b6yPai3ev1X</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B66AE16D-5373-4A1A-AFFE-3DE2F0413F75</gtr:id><gtr:title>Efficacy and effectiveness of infant vaccination against chronic hepatitis B in the Gambia Hepatitis Intervention Study (1986-90) and in the nationwide immunisation program.</gtr:title><gtr:parentPublicationTitle>BMC infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3d1c82ca517f15f9adb36dfc43ba930b"><gtr:id>3d1c82ca517f15f9adb36dfc43ba930b</gtr:id><gtr:otherNames>Peto TJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1471-2334</gtr:issn><gtr:outcomeId>igncH3MT6Ki</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_U190088489</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>D8F3A27D-084A-40BB-A046-087DACE23410</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>3.4  Vaccines</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>